Ocular Complications From Cancer Therapy - Patient Registry and Biobank
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Maryland, Baltimore
About this trial
The purpose of this study is to collect data on patients seen at University of Maryland after undergoing cancer therapy. Previous medications, ocular history, medical history, clinical evaluations, surgical procedures and outcomes will be gathered on the patients who consent to participate. Potential subjects will be enrolled from the clinical practice of the investigator at the time of their eye examination visit. A standard of care exam will be performed pertinent to the reason for the visit. In addition to the standard of care exam, certain biological specimens (ocular surface wash, mucocellular material, corneal filaments, impression cytology, and/or blood) will be collected, stored, and analyzed to obtain immunologic, cellular, or molecular mechanistic insights into disease pathogenesis.
Eligibility criteria
Qualifiers
Adult patients (greater than 18 years of age)
Deny a history of eye diseases (excluding cataract, glaucoma, mild dry eye disease, or history of cataract or refractive surgery)
Patients who have a history of allogenic HSCT with all stem cell sources including bone marrow, PBSC, cord AND/OR patients with a history of prior cancer therapy including BMT, chemotherapy, and immunotherapy
Patients will be recruited after their HSCT or cancer therapy at their ophthalmology appointment
Disqualifiers
Vulnerable populations: neonates, children, prisoners, institutionalized individuals
Inability or refusal to provide informed consent.
History of ocular surgery or ocular disease (except refractive or cataract surgery, mild dry eye disease, or glaucoma).
Vulnerable populations: neonates, children, prisoners, institutionalized individuals
Trial design
Treatments tested in this trial
- Eye exam
Treatment groups
150 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov